A new docetaxel (D) gemcitabine (G) regimen as first-line chemotherapy in advanced non-small cell lung cancer (NSCLC): A phase II study.

被引：0
|
作者：
Morere, JF
Terrioux, P
Brechot, JM
Tredaniel, J
Bouchahda, M
Duhamel, JP
Mandet, J
Brain, E
Beerblock, K
Fellague, R
机构：
[1] Univ Paris 13, CHU Avicenne, Bobigny, France
[2] GERCOR, Paris, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：692S / 692S
页数：1
相关论文
共 50 条
  • [21] Phase I study of docetaxel in combination with Gemcitabine as first line chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC)
    Gatzemeier, U
    Bildat, S
    Harstrick, A
    Eberhardt, W
    Achterrath, W
    Krauss, C
    Wilke, HJ
    ANNALS OF ONCOLOGY, 1998, 9 : 93 - 93
  • [22] First-line chemotherapy with sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer (NSCLC) patients: a multicenter phase II study
    Tibaldi, C.
    Vasile, E.
    Lo Dico, M.
    Antonuzzo, A.
    Di Marsico, R.
    Tartarelli, G.
    Fabbri, A.
    Mazzoni, E.
    Andreuccetti, M.
    Falcone, A.
    EJC SUPPLEMENTS, 2007, 5 (04): : 176 - 176
  • [23] Third-line chemotherapy with gemcitabine or docetaxel in patients with advanced non-small cell lung cancer (NSCLC).
    Morgensztern, D
    Lim, WT
    Subramanian, J
    Viswanathan, A
    Govindan, R
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 694S - 694S
  • [24] Phase II study of meloxicam with carboplatin plus docetaxel in first-line treatment of patients with advanced non-small cell lung cancer (NSCLC)
    Ishida, T.
    Kanazawa, K.
    Oizumi, H.
    Yokouchi, H.
    Yamazaki, K.
    Akie, K.
    Sukoh, N.
    Harada, M.
    Munakata, M.
    Isobe, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [25] First-line single agent of gefitinib in patients (pts) with advanced non-small cell lung cancer (NSCLC): A phase II study.
    Niho, S
    Kubota, K
    Goto, K
    Yoh, K
    Ohmatsu, H
    Kakinuma, R
    Nishiwaki, Y
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 631S - 631S
  • [26] Gemcitabine (G), ifosfamide (I), vinorelbine (N) in advanced non-small cell lung cancer (NSCLC):: A phase II study.
    Morère, JF
    Pailler, MC
    Saintigny, P
    Bréchot, JM
    Morin, F
    Mir, D
    Martinez, A
    Breau, JL
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 705S - 705S
  • [27] Sequential versus concomitant administration of docetaxel and gemcitabine as first-line treatment of advanced non-small cell lung cancer (NSCLC):: results of a phase II/III randomised study
    Manegold, C.
    Thatcher, N.
    Kortsik, C.
    Koschel, G.
    Spengler, W.
    Mezgar, J.
    Schott von Romer, K.
    Pilz, L.
    EJC SUPPLEMENTS, 2005, 3 (02): : 326 - 326
  • [28] A phase II trial of adding cetuximab to cisplatin and gemcitabine as first-line therapy in advanced non-small cell lung cancer (NSCLC)
    Barata, F.
    Parente, B.
    Teixeira, E.
    Costa, A.
    Fernandes, A.
    Pimentel, F. L.
    Carvalho, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [29] A phase II/III randomized study in advanced non-small cell lung cancer (NSCLC) with first-line combination versus sequential gemcitabine and docetaxel: second interim study results
    Mueller, Annette
    Thatcher, Nick
    Kortsik, Cornelius
    Koschel, Gabriele
    Spengler, Werner
    Pitz, Lothar R.
    Mezger, Joerg
    Manegold, Christian
    ANNALS OF ONCOLOGY, 2004, 15 : 168 - 169
  • [30] Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer
    F Cappuzzo
    S Novello
    F De Marinis
    V Franciosi
    M Maur
    A Ceribelli
    V Lorusso
    F Barbieri
    L Castaldini
    E Crucitta
    L Marini
    S Bartolini
    G V Scagliotti
    L Crinò
    British Journal of Cancer, 2005, 93 : 29 - 34
12345